Kidney Cancer Scotland
Kidney Cancer Accord: Consensus Statement
A pathway forward
Non-invasive test that can detect kidney cancer
Renal cell carcinoma (RCC) has poor survival prognosis because it is asymptomatic at an early, more curative stage. Recently, urine perilipin-2 (PLIN-2)... Read More
Folic acid reduces mucositis in mRCC
With the introduction of tyrosine kinase inhibitors (TKI) and mTOR-inhibitors a decade ago, many metastatic RCC patients have received their treatment as... Read More
EC approves Bavencio combination
Merck and Pfizer have announced that the European Commission (EC) has approved Bavencio in combination with axitinib for the first-line treatment of... Read More
Recurrence of RCC after Robotic surgery
WCE 2019: Local Regional Recurrence of RCC after Robotic Partial Nephrectom Abu Dhabi, United Arab Emirates (UroToday.com) Mr. Ethan Wajswol began by introducing... Read More
Microwave Ablation Feasible for cT1b RCC
Microwave ablation is a feasible alternative to nephrectomy in selected patients with renal cell carcinoma (RCC) tumors that are 4 to 7... Read More
Kidney Cancer Clinical Trials: What You Need to Know
Patients with kidney cancer should be thinking about clinical trials at every step of their journey, not just after a line of... Read More
Nutrition in kidney cancer patients
While diet and exercise are a growing concern being addressed in all malignancies, its focus in kidney cancer is still lacking, according... Read More
Cell therapy trials continues after positive kidney cancer readout
Sweden’s Immunicum has announced detailed results from its mid-stage trial of its oncology cell-based immunotherapy ilixadencel, which it says justify further clinical trials... Read More
EU follows US & approves Keytruda for 1st line RCC
Merck & Co/MSD’s PD-1 inhibitor Keytruda received FDA approval earlier in 2019 for use alongside Pfizer’s Inlyta (axitinib) in previously untreated patients... Read More
Ilixadencel/Sunitinib Combo Therapy; Positive Results in mRCC
A combination therapy of ilixadencel plus sunitinib (Sutent) achieved complete tumor responses in patients with metastatic renal cell carcinoma (RCC), according to... Read More
keytruda + axitinib cleared as first-line kidney cancer treatment in EU
Merck & Co/MSD’s Keytruda has added first-line kidney cancer treatment to its ever-lengthening list of approved uses in the EU. The latest... Read More
A guide for talking about advanced cancer
Advice for people living with advanced cancer, their friends and family. We are pleased to present this informative document for the benefit... Read More
Glasgow student develops model kidney that could help train cancer surgeons
The 3D model ‘looks and feels’ like a real kidney. A student has used 3D printing technology to create a model of... Read More
Innovative Research for Advanced Kidney Cancer – David Braun
Alicia Morgans and David Braun discuss his innovative research in metastatic kidney cancer which focuses on understanding and improving immunotherapies in kidney... Read More
Setbacks and Advances in RCC Treatment
Given the variability in disease aggressiveness and the lack of highly predictive biomarkers in renal cell carcinoma (RCC), nothing resembling a “one... Read More
2/1 schedual Sunitinib better than 4/2, says study
The Alternative 2/1 Schedule of Sunitinib is Superior to the Traditional 4/2 Schedule in Patients With Metastatic Renal Cell Carcinoma: A Meta-analysis. Alternate... Read More
Outcomes of patients with mccRCC treated with 2nd line VEGFR-TKI
Prior to the approval of nivolumab, a monoclonal antibody targeting programmed death-1 (PD-1), vascular endothelial growth factor-receptor tyrosine kinase inhibitors (VEGFR-TKIs), specifically... Read More
Why do I volunteer?
By Emma Clark I have chosen to volunteer with Kidney Cancer Scotland for several reasons. I believe volunteering reflects who you are... Read More
Cryoablation of Stage T1b RCC Trial Outcome
Percutaneous Cryoablation of Stage T1b Renal Cell Carcinoma: Safety, Technical Results, and Clinical. The use of percutaneous cryoablation for T1b (4.1-7.0 cm)... Read More
C-reactive protein-albumin ratio as a prognostic factor in RCC
C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma – A data from multi-institutional study in Japan. The C-reactive protein... Read More
NICE recommend nivolumab + ipilimumab combo through CDF
Bristol-Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD)... Read More
Why immunotherapy is not effective for some patients with metastatic kidney cancer
White blood cells known as B cells have been shown to be effective for predicting which cancer patients will respond to immune... Read More
EMA validates Bavencio for review in advanced RCC
The European Medicines Agency (EMA) has validated Merck’s application for Bavencio (avelumab) for the treatment of patients with advanced renal cell carcinoma... Read More